Oral Vancomycin Vs Placebo in the Prevention of Recurrence of Clostridioides Difficile's Infection

A phase III randomized clinical trial in proportion 2:1 in favor of oral vancomycin (experimental treatment), multicentric, national, double-blinded, controlled with placebo. The main objective is to evaluate the effectiveness of treatment with oral vancomycin to reduce the incidence of Clostridioides difficile infection (CDI) in patients who suffered previous CDI and who need further hospitalization and treatment with systemic antibiotic therapy in the 90 days after the first CDI.

As secondary objectives the investigators intend to: * Evaluate the effectiveness of the treatment with oral vancomycin as part of the prophylaxis arsenal to prevent ICD in patients with previous ICD episodes stratified by the number of previous recurrences. * Compare the severity of recurrences in both study groups. * Compare the effectiveness of the treatment with oral vancomycin depending on the type of systemic antibiotic therapy prescribed. * Evaluate the tolerance and the safety of the treatment with oral vancomycin in terms of secondary effects and difficulty in therapeutic compliance. * Evaluate if the treatment with oral vancomycin has an effect in diminishing the severity of ICD recurrences.